Clinical Trials Browser

Phase 1 × Antibodies, Bispecific × Other solid neoplasm × Clear all

NCT05101109 2024-07-31

Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumor